CN114452349A - Maxingshigan powder superfine powder and preparation method thereof - Google Patents
Maxingshigan powder superfine powder and preparation method thereof Download PDFInfo
- Publication number
- CN114452349A CN114452349A CN202210037065.8A CN202210037065A CN114452349A CN 114452349 A CN114452349 A CN 114452349A CN 202210037065 A CN202210037065 A CN 202210037065A CN 114452349 A CN114452349 A CN 114452349A
- Authority
- CN
- China
- Prior art keywords
- parts
- powder
- maxingshigan
- preparation
- raw materials
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000843 powder Substances 0.000 title claims abstract description 80
- 239000008570 maxingshigan Substances 0.000 title claims abstract description 33
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- 239000003814 drug Substances 0.000 claims abstract description 39
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 19
- 239000002994 raw material Substances 0.000 claims abstract description 19
- 241000218671 Ephedra Species 0.000 claims abstract description 18
- 239000002245 particle Substances 0.000 claims abstract description 14
- 229910052602 gypsum Inorganic materials 0.000 claims abstract description 13
- 239000010440 gypsum Substances 0.000 claims abstract description 13
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 12
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 12
- 241001061264 Astragalus Species 0.000 claims abstract description 11
- 241000935235 Fritillaria meleagris Species 0.000 claims abstract description 11
- 244000018633 Prunus armeniaca Species 0.000 claims abstract description 11
- 235000009827 Prunus armeniaca Nutrition 0.000 claims abstract description 11
- 235000006533 astragalus Nutrition 0.000 claims abstract description 11
- 238000002156 mixing Methods 0.000 claims abstract description 11
- 210000004233 talus Anatomy 0.000 claims abstract description 11
- 241000205585 Aquilegia canadensis Species 0.000 claims abstract description 10
- 235000006753 Platycodon grandiflorum Nutrition 0.000 claims abstract description 10
- 235000011477 liquorice Nutrition 0.000 claims abstract description 10
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims abstract description 9
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims abstract description 9
- 238000001035 drying Methods 0.000 claims abstract description 9
- 229940010454 licorice Drugs 0.000 claims abstract description 9
- 238000004140 cleaning Methods 0.000 claims abstract description 7
- 238000007873 sieving Methods 0.000 claims abstract description 7
- 238000005303 weighing Methods 0.000 claims abstract description 7
- 244000274050 Platycodon grandiflorum Species 0.000 claims abstract 3
- 239000000463 material Substances 0.000 claims description 18
- 238000000227 grinding Methods 0.000 claims description 9
- 244000144725 Amygdalus communis Species 0.000 claims description 7
- 235000003893 Prunus dulcis var amara Nutrition 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 6
- 239000004575 stone Substances 0.000 claims description 5
- 238000010521 absorption reaction Methods 0.000 abstract description 5
- 229940079593 drug Drugs 0.000 abstract description 4
- 230000000857 drug effect Effects 0.000 abstract description 4
- 238000010298 pulverizing process Methods 0.000 abstract description 4
- 238000004090 dissolution Methods 0.000 abstract description 3
- 239000000273 veterinary drug Substances 0.000 abstract description 3
- 239000004480 active ingredient Substances 0.000 abstract description 2
- 210000002421 cell wall Anatomy 0.000 abstract description 2
- 230000006378 damage Effects 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 24
- 206010011224 Cough Diseases 0.000 description 12
- 208000006673 asthma Diseases 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 241000287828 Gallus gallus Species 0.000 description 7
- 241000202807 Glycyrrhiza Species 0.000 description 7
- 206010062717 Increased upper airway secretion Diseases 0.000 description 7
- 240000003582 Platycodon grandiflorus Species 0.000 description 7
- 235000013330 chicken meat Nutrition 0.000 description 7
- 208000026435 phlegm Diseases 0.000 description 7
- 230000006870 function Effects 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- -1 sakurane Chemical compound 0.000 description 6
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 230000002458 infectious effect Effects 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- OVHUAFPHYGFWPY-UHFFFAOYSA-N Imperialin Natural products CC1CN2CC3C(CCC4C3CC5C4CC(=O)C6CC(O)CCC56C)CC2C(C)(O)C1 OVHUAFPHYGFWPY-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 206010044302 Tracheitis Diseases 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 201000009837 laryngotracheitis Diseases 0.000 description 4
- XUCIJNAGGSZNQT-JHSLDZJXSA-N (R)-amygdalin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H](C#N)C=2C=CC=CC=2)O1 XUCIJNAGGSZNQT-JHSLDZJXSA-N 0.000 description 3
- ZZAJQOPSWWVMBI-UHFFFAOYSA-N Calycosin Natural products C1=C(O)C(OC)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZZAJQOPSWWVMBI-UHFFFAOYSA-N 0.000 description 3
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 3
- IQDIERHFZVCNRZ-YUYPDVIUSA-N Imperialine Chemical compound C([C@@H]1C(=O)C[C@H]2[C@@H]3CC[C@@H]4[C@]5(C)O)[C@@H](O)CC[C@]1(C)[C@H]2C[C@H]3[C@@H]4CN1[C@H]5CC[C@H](C)C1 IQDIERHFZVCNRZ-YUYPDVIUSA-N 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 229940089837 amygdalin Drugs 0.000 description 3
- YZLOSXFCSIDECK-UHFFFAOYSA-N amygdalin Natural products OCC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC(C#N)c3ccccc3 YZLOSXFCSIDECK-UHFFFAOYSA-N 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 229960003720 enoxolone Drugs 0.000 description 3
- YGHHWSRCTPQFFC-UHFFFAOYSA-N eucalyptosin A Natural products OC1C(O)C(O)C(CO)OC1OC1C(OC(C#N)C=2C=CC=CC=2)OC(CO)C(O)C1O YGHHWSRCTPQFFC-UHFFFAOYSA-N 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000003405 preventing effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000000241 respiratory effect Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 206010010774 Constipation Diseases 0.000 description 2
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 2
- PGCKDCPTJAQQSQ-UHFFFAOYSA-N Isolicoflavonol Chemical compound C1=C(O)C(CC=C(C)C)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 PGCKDCPTJAQQSQ-UHFFFAOYSA-N 0.000 description 2
- 206010068319 Oropharyngeal pain Diseases 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- IUKLSMSEHKDIIP-BZMYINFQSA-N Verticine Chemical compound C([C@@H]1[C@@H](O)C[C@H]2[C@@H]3CC[C@@H]4[C@]5(C)O)[C@@H](O)CC[C@]1(C)[C@H]2C[C@H]3[C@@H]4CN1[C@H]5CC[C@H](C)C1 IUKLSMSEHKDIIP-BZMYINFQSA-N 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- 230000001754 anti-pyretic effect Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- HKQYGTCOTHHOMP-UHFFFAOYSA-N formononetin Chemical compound C1=CC(OC)=CC=C1C1=COC2=CC(O)=CC=C2C1=O HKQYGTCOTHHOMP-UHFFFAOYSA-N 0.000 description 2
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 2
- 229960004949 glycyrrhizic acid Drugs 0.000 description 2
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 2
- 235000019410 glycyrrhizin Nutrition 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 244000000010 microbial pathogen Species 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- IUKLSMSEHKDIIP-UHFFFAOYSA-N petine Natural products CC1(O)C2CCC3C4CC(O)C5CC(O)CCC5(C)C4CC3C2CN2C1CCC(C)C2 IUKLSMSEHKDIIP-UHFFFAOYSA-N 0.000 description 2
- 210000001747 pupil Anatomy 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 231100000167 toxic agent Toxicity 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 150000008130 triterpenoid saponins Chemical class 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
- BUCJHJXFXUZJHL-UHFFFAOYSA-N 1-ethylcyclohexan-1-ol Chemical compound CCC1(O)CCCCC1 BUCJHJXFXUZJHL-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-SFFUCWETSA-N 17α-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-SFFUCWETSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 1
- KSDSYIXRWHRPMN-UHFFFAOYSA-N 4'-O-beta-D-Galactopyranoside-6''-p-Coumaroylprunin-4',5,7-Trihydroxyflavanone Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C2OC3=CC(O)=CC(O)=C3C(=O)C2)C=C1 KSDSYIXRWHRPMN-UHFFFAOYSA-N 0.000 description 1
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- SMDOOINVMJSDPS-UHFFFAOYSA-N Astragaloside Natural products C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(CO)O2)O)=C1 SMDOOINVMJSDPS-UHFFFAOYSA-N 0.000 description 1
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- BDCFUHIWJODVNG-UHFFFAOYSA-N Desmosterol Natural products C1C=C2CC(O)C=CC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 BDCFUHIWJODVNG-UHFFFAOYSA-N 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010013952 Dysphonia Diseases 0.000 description 1
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 241000555682 Forsythia x intermedia Species 0.000 description 1
- NGGYSPUAKQMTNP-UHFFFAOYSA-N Glabrene Chemical compound C1=C(O)C=C2OCC(C3=C4OC(C=CC4=C(O)C=C3)(C)C)=CC2=C1 NGGYSPUAKQMTNP-UHFFFAOYSA-N 0.000 description 1
- KKLOCFOZPFGVBB-UHFFFAOYSA-N Glabrene Natural products C1=C(O)C=C2OCC(C3=CC=C4OC(C=CC4=C3O)(C)C)=CC2=C1 KKLOCFOZPFGVBB-UHFFFAOYSA-N 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 208000031361 Hiccup Diseases 0.000 description 1
- 208000010473 Hoarseness Diseases 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- 206010020741 Hyperpyrexia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- HVPKALQHGQMJER-XOUPSZAESA-N Isoastragaloside I Chemical compound CC(=O)O[C@@H]1[C@@H](O)[C@H](OC(=O)C)CO[C@H]1O[C@@H]1C(C)(C)[C@@H]2[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C[C@H]3[C@]4(C)C[C@H](O)[C@H]([C@]5(C)O[C@@H](CC5)C(C)(C)O)[C@@]4(C)CC[C@@]43C[C@@]42CC1 HVPKALQHGQMJER-XOUPSZAESA-N 0.000 description 1
- NWLKARBSFUGLOG-UHFFFAOYSA-N Isoastragaloside I Natural products CC(=O)OC1COC(OC2CCC34CC35CCC6(C)C(C(O)CC6(C)C5CC(OC7OC(CO)C(O)C(O)C7O)C4C2(C)C)C8(C)CC(CO8)C(C)(C)O)C(OC(=O)C)C1O NWLKARBSFUGLOG-UHFFFAOYSA-N 0.000 description 1
- SMZYCXAYGPGYRS-NGTUZWGPSA-N Isoastragaloside II Chemical compound O[C@@H]1[C@@H](OC(=O)C)[C@H](O)CO[C@H]1O[C@@H]1C(C)(C)[C@@H]2[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C[C@H]3[C@]4(C)C[C@H](O)[C@H]([C@]5(C)O[C@@H](CC5)C(C)(C)O)[C@@]4(C)CC[C@@]43C[C@@]42CC1 SMZYCXAYGPGYRS-NGTUZWGPSA-N 0.000 description 1
- QEQVFWRMJLHKMM-UHFFFAOYSA-N Isoastragaloside II Natural products CC(=O)OC1C(O)COC(OC2CCC34CC35CCC6(C)C(C(O)CC6(C)C5CC(OC7OC(CO)C(O)C(O)C7O)C4C2(C)C)C8(C)CC(CO8)C(C)(C)O)C1O QEQVFWRMJLHKMM-UHFFFAOYSA-N 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- 102000003820 Lipoxygenases Human genes 0.000 description 1
- 108090000128 Lipoxygenases Proteins 0.000 description 1
- DEMKZLAVQYISIA-ONJCETCRSA-N Liquiritin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1ccc([C@@H]2Oc3c(C(=O)C2)ccc(O)c3)cc1 DEMKZLAVQYISIA-ONJCETCRSA-N 0.000 description 1
- DEMKZLAVQYISIA-UHFFFAOYSA-N Liquirtin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C2OC3=CC(O)=CC=C3C(=O)C2)C=C1 DEMKZLAVQYISIA-UHFFFAOYSA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- QMNWISYXSJWHRY-XWJCTJPOSA-N astragaloside Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)C4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)CC3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-XWJCTJPOSA-N 0.000 description 1
- QMNWISYXSJWHRY-YLNUDOOFSA-N astragaloside IV Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)[C@H]4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)C[C@H]3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-YLNUDOOFSA-N 0.000 description 1
- QMNWISYXSJWHRY-BCBPIKMJSA-N astragaloside IV Natural products CC(C)(O)[C@@H]1CC[C@@](C)(O1)[C@H]2[C@@H](O)C[C@@]3(C)[C@@H]4C[C@H](O[C@@H]5O[C@H](CO)[C@H](O)[C@@H](O)[C@H]5O)[C@H]6C(C)(C)[C@H](CC[C@@]67C[C@@]47CC[C@]23C)O[C@@H]8OC[C@@H](O)[C@H](O)[C@H]8O QMNWISYXSJWHRY-BCBPIKMJSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 150000004775 coumarins Chemical class 0.000 description 1
- PFKIBRPYVNVMRU-UHFFFAOYSA-N cyclosieversioside F Natural products CC(C)(O)C1COC(C)(C1)C2C(O)CC3(C)C4CC(OC5OC(CO)C(O)C(O)C5O)C6C(C)(C)C(CCC67CC47CCC23C)OC8OCC(O)C(O)C8O PFKIBRPYVNVMRU-UHFFFAOYSA-N 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- AVSXSVCZWQODGV-DPAQBDIFSA-N desmosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@@H](CCC=C(C)C)C)[C@@]1(C)CC2 AVSXSVCZWQODGV-DPAQBDIFSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002888 effect on disease Effects 0.000 description 1
- 229960003399 estrone Drugs 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- RIKPNWPEMPODJD-UHFFFAOYSA-N formononetin Natural products C1=CC(OC)=CC=C1C1=COC2=CC=CC=C2C1=O RIKPNWPEMPODJD-UHFFFAOYSA-N 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- SMZYCXAYGPGYRS-UHFFFAOYSA-N isoastragalosides II Natural products OC1C(OC(=O)C)C(O)COC1OC1C(C)(C)C2C(OC3C(C(O)C(O)C(CO)O3)O)CC3C4(C)CC(O)C(C5(C)OC(CC5)C(C)(C)O)C4(C)CCC43CC42CC1 SMZYCXAYGPGYRS-UHFFFAOYSA-N 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- DEMKZLAVQYISIA-ZRWXNEIDSA-N liquiritin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C([C@H]2OC3=CC(O)=CC=C3C(=O)C2)C=C1 DEMKZLAVQYISIA-ZRWXNEIDSA-N 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 1
- 235000009498 luteolin Nutrition 0.000 description 1
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000010016 myocardial function Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000013594 poultry meat Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- GSZUGBAEBARHAW-UHFFFAOYSA-N sophoraflavone B Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C=2OC3=CC(O)=CC=C3C(=O)C=2)C=C1 GSZUGBAEBARHAW-UHFFFAOYSA-N 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 210000001913 submandibular gland Anatomy 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 210000005090 tracheal smooth muscle Anatomy 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 230000013948 uterine smooth muscle contraction Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 210000001213 vestibule labyrinth Anatomy 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- MPDGHEJMBKOTSU-PMTKVOBESA-N β-glycyrrhetinic acid Chemical compound C([C@@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-PMTKVOBESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/17—Gnetophyta, e.g. Ephedraceae (Mormon-tea family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/346—Platycodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/634—Forsythia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8966—Fritillaria, e.g. checker lily or mission bells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/13—Preparation or pretreatment of starting material involving cleaning, e.g. washing or peeling
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/15—Preparation or pretreatment of starting material involving mechanical treatment, e.g. chopping up, cutting or grinding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/17—Preparation or pretreatment of starting material involving drying, e.g. sun-drying or wilting
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a Maxingshigan powder superfine powder and a preparation method thereof, belonging to the technical field of veterinary drugs and comprising the following raw materials in parts by weight: 12-20 parts of ephedra, 9-16 parts of bitter apricot seed, 10-18 parts of gypsum, 3-8 parts of liquorice, 7-13 parts of honeysuckle, 7-14 parts of fructus forsythiae, 6-12 parts of astragalus, 5-10 parts of platycodon grandiflorum and 6-12 parts of thunberg fritillary bulb. The preparation method comprises the following steps: weighing the raw materials according to the parts by weight, cleaning, airing and drying; pulverizing and sieving the dried components to obtain medicinal powder; mixing the medicinal powder, and micronizing. The ultrafine powder of the ephedra, apricot kernel, gypsum and licorice powder and the preparation method thereof do not damage the active ingredients of the medicine and do not threaten safe medication, and the medicine has the particle size of 10-20 mu m and uniform granularity. Can completely release effective components of the medicine, improve cell wall breaking rate, increase absorption and dissolution degree and drug effect, and has high bioavailability and rapid onset time of the medicine.
Description
Technical Field
The invention relates to the technical field of veterinary drugs, and in particular relates to Maxingshigan powder superfine powder and a preparation method thereof.
Background
The veterinary drug of the Maxingshigan powder has the main effects of clearing away heat and toxic materials, ventilating the lung and relieving cough, dissolving hidden phlegm, relieving asthma and relieving sore throat, mainly treating lung heat cough and asthma, and is suitable for respiratory type branch and throat passing and chronic respiratory tract, and hiccups, coughs and wheezing caused by vaccine reaction, such as bubbly frog, laryngalgia, larynx swelling and cheese-like respiratory syndrome in the mouth-opening respiratory trachea due to weather change, four seasons alternation, drug emergency. However, the existing veterinary ephedra, apricot, gypsum and licorice powder mainly adopts water decoction or coarse powder, has the defects of large dosage, coarse dosage form, poor appearance and the like, cannot fully release effective components, has low bioavailability, seriously influences the quality and clinical treatment effect of the traditional Chinese medicine and restricts the application of the traditional Chinese medicine; meanwhile, the existing Maxingshigan powder has poor palatability, slow dissolving speed, is not beneficial to the medication of livestock and poultry, is slowly absorbed, and delays the treatment effect on diseases.
During the processing and production of the traditional Chinese medicine, a proper treatment form is adopted, so that the release rate of the effective components is improved, the medicine effect is enhanced, and the dosage is saved. The medicine can increase the surface area of the medicine, promote the dissolution and absorption of the medicine and accelerate the leaching of the effective components in the medicinal materials by crushing the medicine. The superfine grinding technology has unique advantages in the grinding of traditional Chinese medicines due to the advantage of deep resource. The technology makes up for the defects of the traditional crushing process, improves the texture uniformity of the powder, improves the bioavailability of the medicament, accelerates the absorption of the medicament and enhances the medicament effect.
Disclosure of Invention
The invention aims to provide the Maxingshigan submicron powder and the preparation method thereof, which are used for solving the problems in the prior art.
In order to achieve the purpose, the invention provides the following scheme:
the invention provides Maxingshigan powder superfine powder which is prepared from the following raw materials in parts by weight: 12-20 parts of ephedra, 9-16 parts of bitter almond, 10-18 parts of gypsum, 3-8 parts of liquorice, 7-13 parts of honeysuckle, 7-14 parts of fructus forsythiae, 6-12 parts of astragalus, 5-10 parts of platycodon grandiflorum and 6-12 parts of thunberg fritillary bulb.
Preferably, the Maxingshigan submicron powder is prepared from the following raw materials in parts by weight: 16 parts of ephedra, 12 parts of bitter almond, 15 parts of gypsum, 5 parts of liquorice, 10 parts of honeysuckle, 10 parts of fructus forsythiae, 8 parts of astragalus, 6 parts of platycodon grandiflorum and 8 parts of thunberg fritillary bulb.
The invention also provides a preparation method of the Maxingshigan submicron powder, which comprises the following steps:
(1) weighing the raw materials according to the weight parts, cleaning, airing and drying;
(2) crushing and sieving the components dried in the step (1) to obtain medicinal material powder;
(3) and (3) uniformly mixing the medicinal material powder obtained in the step (2), and carrying out superfine grinding to obtain the traditional Chinese medicine.
Further, drying the raw materials in the step (1) until the moisture content is 5% -9%.
Further, the pulverization in the step (2) is performed at room temperature until the particle size is 70-90 meshes.
Further, the mixing in the step (3) is carried out in a mixer, and the mixing time is 20-40 min.
Further, the superfine grinding in the step (3) is airflow superfine grinding.
Further, the air current ultra-fine pulverization is carried out in a supersonic air current pulverizer.
Further, the micronization is carried out at a temperature of 0 to 10 ℃ and a pressure of 0.8 to 1.0 MPa.
Further, the particle size of the superfine powder in the step (3) is 10-20 μm.
The traditional Chinese medicine provided by the invention has the following effects of the raw materials:
the herba Ephedrae has effects of inducing sweat, dispelling cold, dispersing lung qi, relieving asthma, and inducing diuresis to alleviate edema. Has adrenomimetic nerve effect on cardiovascular system, and the blood pressure increasing effect can generate rapid tolerance; has effects of relieving asthma, relieving cough, and eliminating phlegm; can increase sweat gland secretion; has obvious diuretic effect; has antiallergic and antiinflammatory effects; has antipyretic effect and pathogenic microorganism resisting effect at different degrees; can excite the center and influence the transmission of nerve and muscle.
Semen Armeniacae amarum has effects of lowering qi, relieving cough and asthma, and loosening bowel to relieve constipation. Contains amygdalin, fatty oil, amygdalin, sakurane, estrone, alpha-estradiol, desmosterol, amygdalin, cholesterol, etc. Can protect liver; relieving cough and asthma; loosening bowel to relieve constipation; anti-tumor; anti-inflammatory and anti-cancer; resistance to mutation; and (3) killing roundworms.
Gypsum Fibrosum has effects of clearing heat, lowering fire, relieving restlessness and quenching thirst. Gypsum Fibrosum has antipyretic, thirst quenching, and immune system regulating effects; can inhibit hyperpyrexia of pituitary gland, adrenal gland, submandibular gland, prostate, pancreas, and testis due to excessive internal heat; can promote spleen and thymus function.
The liquorice can tonify spleen and qi, relieve cough and eliminate phlegm, relieve urgency and relieve pain and harmonize medicine property. Mainly comprises liquiritin, glycyrrhizic acid, glycyrrhizin, syringene oxide, glycyrrhetinic acid, 18 alpha-hydroxy glycyrrhetinic acid, isoglycyrrhetinic acid, glycyrrhetinic acid, formononetin, neolicochalcone D, glabrene aglycone, isolicoflavonol, triterpenoid saponin, coumarin, etc. Has adrenocortical hormone action, antiinflammatory, antiulcer, antiallergic, anticancer, antibacterial, antiviral, pancreatic secretion promoting, in vitro intestine inhibiting, immunity regulating, cough relieving, phlegm eliminating, mutation resisting, toxic substance removing, antioxidant, ear vestibule function protecting, diuretic, liver protecting, arteriosclerosis preventing, cerebral ischemia resisting, and diabetes complication preventing effects.
Flos Lonicerae has effects of clearing away heat and toxic materials, and cooling and dispelling wind heat, and contains luteolin, inositol 1%, volatile oil, terpenes, phenolic acid, etc. Has effects in resisting pathogenic microorganism, resisting virus, resisting inflammation, relieving fever, promoting phagocytic function of inflammatory cell, reducing blood lipid, exciting central nervous system, resisting fertility, preventing gastric ulcer, and exciting uterus.
Fructus forsythiae has effects of clearing away heat and toxic materials, relieving swelling, and dispersing pathogen accumulation, and contains lignanoids, flavonoids, volatile components, phenethyl, ethyl cyclohexanol, triterpenes, and coumarins. Is antimicrobial; inhibiting phosphodiesterase, lipoxygenase; stopping vomiting; anti-liver damage; anti-inflammatory; inhibiting elastase activity; reduce spontaneous hypertension, etc.
Radix astragali has effects of invigorating qi, invigorating yang, consolidating superficial resistance, arresting sweating, inducing diuresis, relieving swelling, promoting fluid production, nourishing blood, activating stagnancy, relieving arthralgia, removing toxic substance, expelling pus, healing sore, and promoting granulation. Mainly contains astragaloside IV, astragaloside, calycosin glucoside, calycosin, isoastragaloside I, isoastragaloside II, triterpenoid saponin, flavone and polysaccharide. The astragalus has the effect and function of promoting the metabolism of nucleic acid; enhancing hematopoietic function; improving myocardial function, and resisting myocardial infarction; has antioxidant, antiviral, anticancer, renal function improving, and renal histopathological changes improving effects.
Radix Platycodi has effects of dispersing lung qi, relieving sore throat, eliminating phlegm, and expelling pus. Can be used for treating cough with excessive phlegm, chest distress, pharyngalgia, hoarseness, lung carbuncle, and purulent vomiting.
Thunberg fritillary bulb has the functions of clearing heat, resolving hard mass, eliminating phlegm and relieving cough, contains sterol alkaloid peimine, namely peimine, peiminine, thunbergine, peiminone, peiminine, iso-peiminine, peiminine glycoside, peiminine, choline, Obetidine and the like, and contains various diterpenoid compounds. Has antitussive, tranquilizing, antiasthmatic, pupil dilating, blood pressure regulating, analgesic, blood sugar increasing, and expectorant effects. Can dilate tracheal smooth muscle and strengthen uterine smooth muscle contraction; heart rate may be slowed; dilate pupil, inhibit salivary secretion; can raise blood sugar, etc.
Compared with the prior art, the invention has the following technical effects:
the invention adds honeysuckle, forsythia, astragalus, balloonflower root and thunberg fritillary bulb on the basis of the traditional formula of the Maxingshigan powder, and the synergistic effect can be generated by matching the usage, thereby enhancing the drug effect, promoting the metabolism of the organism and having obvious treatment effect on respiratory diseases such as wind cold, asthma, cough and the like.
The ultrafine powder of the ephedra, apricot kernel, gypsum and licorice powder and the preparation method thereof do not damage the active ingredients of the medicine and do not threaten safe medication, and the medicine has the particle size of 10-20 mu m and uniform granularity. Can completely release effective components of the medicine, improve cell wall breaking rate, increase absorption and dissolution degree and drug effect, and has high bioavailability and rapid onset time of the medicine. But the grain diameter of the superfine powder can not be too small to cause direct permeation through the digestive tract barrier and interfere the absorption of the medicine. The traditional Chinese medicine composition has stable drug effect, does not influence the effect due to overlong time, has higher curative effect of treating the asthma and the cough of animals, takes effect quickly, has longer maintenance time, has wide market, reduces the death probability of the animals due to the respiratory diseases of the animals, and shortens the economic loss.
Detailed Description
Reference will now be made in detail to various exemplary embodiments of the invention, the detailed description should not be construed as limiting the invention but as a more detailed description of certain aspects, features and embodiments of the invention.
It is to be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. Further, for numerical ranges in this disclosure, it is understood that each intervening value, between the upper and lower limit of that range, is also specifically disclosed. Every smaller range between any stated value or intervening value in a stated range and any other stated or intervening value in a stated range is encompassed within the invention. The upper and lower limits of these smaller ranges may independently be included or excluded in the range.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although only preferred methods and materials are described herein, any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention. All documents mentioned in this specification are incorporated by reference herein for the purpose of disclosing and describing the methods and/or materials associated with the documents. In case of conflict with any incorporated document, the present specification will control.
It will be apparent to those skilled in the art that various modifications and variations can be made in the specific embodiments of the present disclosure without departing from the scope or spirit of the disclosure. Other embodiments will be apparent to those skilled in the art from consideration of the specification. The specification and examples are exemplary only.
As used herein, the terms "comprising," "including," "having," "containing," and the like are open-ended terms that mean including, but not limited to.
Example 1
The ultrafine powder of the Maxingshigan powder is composed of the following raw materials in parts by weight: 12 parts of ephedra, 9 parts of bitter almond, 10 parts of gypsum, 3 parts of liquorice, 7 parts of honeysuckle, 7 parts of fructus forsythiae, 6 parts of astragalus, 5 parts of platycodon grandiflorum and 6 parts of thunberg fritillary bulb.
Example 2
The ultrafine powder of the Maxingshigan powder is composed of the following raw materials in parts by weight: 20 parts of ephedra, 16 parts of bitter apricot seed, 18 parts of gypsum, 8 parts of liquorice, 13 parts of honeysuckle, 14 parts of fructus forsythiae, 12 parts of astragalus, 10 parts of platycodon grandiflorum and 12 parts of thunberg fritillary bulb.
Example 3
The ultrafine powder of the Maxingshigan powder is composed of the following raw materials in parts by weight: 15 parts of ephedra, 12 parts of bitter almond, 14 parts of gypsum, 5 parts of liquorice, 10 parts of honeysuckle, 10 parts of fructus forsythiae, 10 parts of astragalus, 7 parts of platycodon grandiflorum and 8 parts of thunberg fritillary bulb.
Example 4
The ultrafine powder of the Maxingshigan powder is composed of the following raw materials in parts by weight: 16 parts of ephedra, 12 parts of bitter almond, 15 parts of gypsum, 5 parts of liquorice, 10 parts of honeysuckle, 10 parts of fructus forsythiae, 8 parts of astragalus, 6 parts of platycodon grandiflorum and 8 parts of thunberg fritillary bulb.
Example 5
The preparation method of the Maxingshigan submicron powder in the embodiment 1 comprises the following steps:
(1) weighing the raw materials according to the weight parts, cleaning, airing and drying until the moisture content is 5%;
(2) crushing and sieving the dried components at room temperature to obtain medicinal material powder with the granularity of 70 meshes;
(3) mixing the medicinal material powder obtained in the step (2) in a mixer for 20min, adding the primarily crushed traditional Chinese medicine particles into a supersonic airflow crusher for superfine crushing, wherein the particle size of the crushed traditional Chinese medicine is 20 μm, and thus obtaining the ultrafine powder of the ephedra, apricot stone and licorice powder; wherein the supersonic jet mill is operated at a temperature of 10 ℃ and a pressure of 1.0 MPa.
Example 6
The preparation method of the Maxingshigan submicron powder in the embodiment 2 comprises the following steps: the method comprises the following steps:
(1) weighing the raw materials according to the weight parts, cleaning, airing and drying until the moisture content is 9%;
(2) pulverizing the dried components at room temperature, and sieving to obtain medicinal powder with particle size of 80 meshes;
(3) mixing the medicinal material powder obtained in the step (2) in a mixer for 40min, adding the primarily crushed traditional Chinese medicine particles into a supersonic airflow crusher for superfine crushing, wherein the particle size of the crushed traditional Chinese medicine is 15 μm, and thus obtaining the ultrafine powder of the ephedra, apricot stone and licorice powder; wherein the supersonic jet mill is operated at a temperature of 0 deg.C and a pressure of 0.8 MPa.
Example 7
The preparation method of the Maxingshigan submicron powder of the embodiment 3 comprises the following steps:
(1) weighing the raw materials according to the weight parts, cleaning, airing and drying until the moisture content is 7%;
(2) crushing and sieving the dried components at room temperature to obtain medicinal material powder with the granularity of 75 meshes;
(3) mixing the medicinal material powder obtained in the step (2) in a mixer for 35min, adding the primarily crushed traditional Chinese medicine particles into a supersonic airflow crusher for superfine crushing, wherein the particle size of the crushed traditional Chinese medicine is 12 μm, and thus obtaining the ultrafine powder of the ephedra, apricot stone and licorice powder; wherein the supersonic jet mill is operated at a temperature of 7 ℃ and a pressure of 1.0 MPa.
Example 8
The preparation method of the Maxingshigan submicron powder of the embodiment 4 comprises the following steps:
(1) weighing the raw materials according to the weight part, cleaning, airing and drying until the moisture content is 8%;
(2) crushing and sieving the dried components at room temperature to obtain medicinal material powder with the granularity of 90 meshes;
(3) mixing the medicinal material powder obtained in the step (2) in a mixer for 30min, adding the primarily crushed traditional Chinese medicine particles into a supersonic airflow crusher for superfine crushing, wherein the particle size of the crushed traditional Chinese medicine is 10 μm, and thus obtaining the ultrafine powder of the ephedra, apricot stone and licorice powder; wherein the supersonic jet mill is operated at a temperature of 5 ℃ and a pressure of 0.9 MPa.
Test examples
Clinical treatment observation of Maxingshigan powder ultramicro powder preparation on chicken infectious laryngotracheitis
The Roman laying hens which are attacked 2 weeks after the development of the test animals are diagnosed as the chicken infectious laryngotracheitis according to the attack condition, clinical manifestation and pathological change and laboratory detection.
500 sick chickens with similar size and weight, which are diagnosed as the infectious bronchitis, are randomly divided into 5 groups of 100 chickens, wherein 1-4 groups are test groups, and 5 groups are control groups. The treatment test is carried out by adding the Maxingshigan powder superfine powder into 1 group according to the proportion of 0.5 percent, 2 groups according to the proportion of 1 percent, 3 groups according to the proportion of 1.5 percent and 4 groups according to the proportion of 2 percent in the feed, the medicine is continuously applied for 7 days, and the control group is not added with any medicine, and the control group is uniformly fed and managed (the test result is shown in table 1).
TABLE 1 therapeutic effect of Maxingshigan powder on infectious laryngotracheitis of chicken
| Group of | Number of sick chickens | Number of cure | High efficiency | Cure rate | Time to cure |
| 1 | 100 pieces of | 60 pieces of | 90％ | 60％ | 7 days |
| 2 | 100 pieces of | 78 are only | 97％ | 78％ | 5 days |
| 3 | 100 pieces of | 89 are only | 99％ | 89％ | 4 days |
| 4 | 100 pieces of | 94 are | 100％ | 94％ | 3 days |
| 5 | 100 pieces of | 22 only | 50％ | 22％ | 10 days |
The test result shows that: the cure rate of the treated test group was significantly higher than that of the control group. The treatment effect of the ephedra, apricot kernel, gypsum and licorice powder on the infectious laryngotracheitis of the chicken is obvious.
The above-described embodiments are only intended to illustrate the preferred embodiments of the present invention, and not to limit the scope of the present invention, and various modifications and improvements made to the technical solution of the present invention by those skilled in the art without departing from the spirit of the present invention should fall within the protection scope defined by the claims of the present invention.
Claims (10)
1. The ultrafine powder of the Maxingshigan powder is characterized in that: the Maxingshigan submicron powder is prepared from the following raw materials in parts by weight: 12-20 parts of ephedra, 9-16 parts of bitter almond, 10-18 parts of gypsum, 3-8 parts of liquorice, 7-13 parts of honeysuckle, 7-14 parts of fructus forsythiae, 6-12 parts of astragalus, 5-10 parts of platycodon grandiflorum and 6-12 parts of thunberg fritillary bulb.
2. The ultrafine powder of the ephedra, apricot stone and licorice powder as claimed in claim 1, which is characterized in that: the Maxingshigan submicron powder is prepared from the following raw materials in parts by weight: 16 parts of ephedra, 12 parts of bitter almond, 15 parts of gypsum, 5 parts of liquorice, 10 parts of honeysuckle, 10 parts of fructus forsythiae, 8 parts of astragalus, 6 parts of platycodon grandiflorum and 8 parts of thunberg fritillary bulb.
3. The method for preparing the Maxingshigan submicron powder according to any one of the claims 1 to 2, which is characterized in that: the preparation method comprises the following steps:
(1) weighing the raw materials according to the weight parts, cleaning, airing and drying;
(2) crushing and sieving the components dried in the step (1) to obtain medicinal material powder;
(3) and (3) uniformly mixing the medicinal material powder obtained in the step (2), and carrying out superfine grinding to obtain the traditional Chinese medicine.
4. The preparation method of the Maxingshigan submicron powder as claimed in claim 3, which is characterized in that: and (2) drying the raw materials in the step (1) until the moisture content is 5-9%.
5. The preparation method of the Maxingshigan submicron powder as claimed in claim 3, which is characterized by comprising the following steps: the crushing in the step (2) is performed at room temperature until the granularity is 70-90 meshes.
6. The preparation method of the Maxingshigan submicron powder as claimed in claim 3, which is characterized in that: the mixing in the step (3) is carried out in a mixer, and the mixing time is 20-40 min.
7. The preparation method of the Maxingshigan submicron powder as claimed in claim 3, which is characterized in that: the superfine grinding in the step (3) is airflow superfine grinding.
8. The preparation method of the Maxingshigan submicron powder as claimed in claim 7, which is characterized in that: the airflow ultramicro crushing is carried out in a supersonic airflow crusher.
9. The preparation method of the Maxingshigan submicron powder as claimed in claim 8, which is characterized in that: the superfine grinding is carried out at the temperature of 0-10 ℃ and the pressure of 0.8-1.0 MPa.
10. The preparation method of the Maxingshigan submicron powder as claimed in claim 3, which is characterized in that: the particle size of the superfine powder in the step (3) is 10-20 μm.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210037065.8A CN114452349A (en) | 2022-01-13 | 2022-01-13 | Maxingshigan powder superfine powder and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210037065.8A CN114452349A (en) | 2022-01-13 | 2022-01-13 | Maxingshigan powder superfine powder and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114452349A true CN114452349A (en) | 2022-05-10 |
Family
ID=81408850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210037065.8A Pending CN114452349A (en) | 2022-01-13 | 2022-01-13 | Maxingshigan powder superfine powder and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114452349A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1927303A (en) * | 2006-08-29 | 2007-03-14 | 天津生机集团有限公司 | Chinese medicine for treating chicken respiratory tract disease |
| CN101810699A (en) * | 2009-12-17 | 2010-08-25 | 河南省康星药业有限公司 | Preparation method of Maxingshigan submicron powder |
| CN108815319A (en) * | 2018-07-27 | 2018-11-16 | 广西昭平县南越生态养殖有限公司 | A kind of Chinese medicine preparation for treating poultry mycoplasma infection |
-
2022
- 2022-01-13 CN CN202210037065.8A patent/CN114452349A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1927303A (en) * | 2006-08-29 | 2007-03-14 | 天津生机集团有限公司 | Chinese medicine for treating chicken respiratory tract disease |
| CN101810699A (en) * | 2009-12-17 | 2010-08-25 | 河南省康星药业有限公司 | Preparation method of Maxingshigan submicron powder |
| CN108815319A (en) * | 2018-07-27 | 2018-11-16 | 广西昭平县南越生态养殖有限公司 | A kind of Chinese medicine preparation for treating poultry mycoplasma infection |
Non-Patent Citations (2)
| Title |
|---|
| 程晶晶,等: "黄芪麻杏石甘汤对鸡传染性喉气管炎病毒在体内增殖变化的影响", 《黑龙江畜牧兽医》 * |
| 陈宝玉,等: "中药超微粉散剂的应用前景", 《今日畜牧兽医》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2015172618A1 (en) | Anti-tumor traditional chinese medicine, preparation method therefor, and uses thereof | |
| CN104208393B (en) | It is a kind of to be used to prevent Chinese medicine composition of infectious bronchitis of chicken and preparation method thereof | |
| CN114452349A (en) | Maxingshigan powder superfine powder and preparation method thereof | |
| CN116115673A (en) | Traditional Chinese medicine formula for clearing heat and freeing nose and preparation process | |
| WO2023125798A1 (en) | Traditional chinese medicine composition and preparation method and application thereof | |
| CN102430113B (en) | Compound propolis composition for treating porcine pseudorabies and preparation method thereof | |
| CN102188483B (en) | Extract for treating pharyngolaryngitis and preparation method thereof | |
| CN111375038B (en) | Traditional Chinese medicine bath composition for treating psoriasis as well as preparation method and application thereof | |
| WO2018090276A1 (en) | Chinese medicine composition for prevention and treatment of combined allergic rhinitis and asthma syndrome and preparation method thereof | |
| WO2018090345A1 (en) | Gel for prevention and treatment of respiratory allergic disease and preparation method thereof | |
| CN101904931A (en) | Medicament for treating beriberi and preparation method thereof | |
| CN101129543A (en) | Chinese ephedra canopy powder | |
| CN108904684A (en) | A kind of cough relieving powder dry suspensoid agent for animals and preparation method thereof | |
| CN1730068A (en) | Medicinal powder for treating asthma and cough | |
| CN112402565B (en) | Traditional Chinese medicine composition for treating gonarthromeningitis and preparation method thereof | |
| CN112402566B (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating gonarthromeningitis | |
| CN111195299B (en) | Chinese medicinal composition for treating hepatic fibrosis and preparation method thereof | |
| CN105998776A (en) | Traditional Chinese medicinal composition for treating equine rhinopneumonitis and preparation method thereof | |
| CN105311212A (en) | Traditional Chinese medicine for treating chronic nasosinusitis and preparation method | |
| CN101229348A (en) | Chinese traditional medicine compounds for treating tumour and preparing method thereof | |
| CN102078515B (en) | Chinese herbal medicine pill for treating chronic pharyngitis | |
| CN104474220A (en) | Medicine for treating bronchial asthma and preparation method thereof | |
| CN104758749A (en) | Traditional Chinese medicine composition for treating liver cancer | |
| CN103550550B (en) | Traditional Chinese medicine for treating phlegm and blood stasis type gall disease | |
| CN112107645A (en) | A Chinese medicinal composition for improving reproductive function and improving life quality |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220510 |
|
| RJ01 | Rejection of invention patent application after publication |